Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma.

[en] BACKGROUND: Asthma is associated with accelerated rate of lung function (FEV1) decline. OBJECTIVE: To determine predictive factors associated with FEV1 decline in adult asthma. METHODS: A retrospective study was conducted in 229 asthmatics recruited from the University Asthma Clinic of Liege. Subjects had at least two visits with post-bronchodilation (post-BD) FEV1 and minimum one year between them. A multivariable linear regression analysis was conducted in order to come up with factors associated with lung function decline. RESULTS: Post-BD FEV1 decline in % predicted. y(-1) was 0.2 (95%CI -2.0 to 2.8) in the overall population. Our population was made up of mild to moderate asthmatics [1] for 58%, aged 50 (41-60) years old, 62% were female and 59% were atopic. Median ICS dose was 1000mug beclomethasone equivalent (CFC)/day with 81% treated at baseline. Time between visits was 46.8+/-32.1 months. The univariate linear regression analysis revealed a negative association between % predicted FEV1 decline and baseline ACQ (p<0.0001) and blood eosinophils (% and/mm(3)) (p<0.0001 and p<0.0001). A positive association was found between % predicted FEV1 decline and baseline pre-BD FEV1 (mL) values (p=0.001), blood neutrophils (%) (p=0.02), change in blood eosinophils (%) (p<0.0001), time between visits (months) (p<0.0001). The predictive variables for accelerated decline highlighted by the multivariable analysis (r(2)=0.39) were change in blood eosinophils (%) over time (p=0.002) and time between visits (months) (p<0.0001). CONCLUSION: These findings highlight a new value for blood eosinophil counts as their increase over time predicts greater lung function decline in asthma.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Graff, Sophie ; Université de Liège - ULiège > I3-Pneumology

Demarche, Sophie ; Université de Liège - ULiège > Doct. sc. bioméd. & pharma. (Bologne)

HENKET, Monique ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme

PAULUS, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de l'asthme

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

SCHLEICH, FLorence ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie

Language :

English

Title :

Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma.

Publication date :

June 2019

Journal title :

Respiratory Medicine

ISSN :

0954-6111

eISSN :

1532-3064

Publisher :

Elsevier, Oxford, United Kingdom

Volume :

152

Pages :

60-66

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 13 December 2019

Statistics

Number of views

134 (12 by ULiège)

Number of downloads

172 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43 (2014), 343–373.
Bai, T.R., Knight, D.A., Structural changes in the airways in asthma: observations and consequences. Clin. Sci. 108 (2005), 463–477.
Lange, P., Parner, J., Vestbo, J., Schnohr, P., Jensen, G., A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 339 (1998), 1194–1200.
Peat, J.K., Woolcock, A.J., Cullen, K., Rate of decline of lung function in subjects with asthma. Eur. J. Respir. Dis. 70 (1987), 171–179.
Broekema, M., Volbeda, F., Timens, W., Dijkstra, A., Lee, N.A., Lee, J.J., et al. Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV(1). Respir. Med. 104 (2010), 1254–1262.
Connolly, C.K., Chan, N.S., Prescott, R.J., The relationship between age and duration of asthma and the presence of persistent obstruction in asthma. Postgrad. Med. 64 (1988), 422–425.
Enright, R.L., Connett, J.E., Bailey, W.C., The FEV1/FEV6 predicts lung function decline in adult smokers. Respir. Med. 96 (2002), 444–449.
Brutsche, M.H., Downs, S.H., Schindler, C., Gerbase, M.W., Schwartz, J., Frey, M., et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 61 (2006), 671–677.
Ulrik, C.S., Lange, P., Decline of lung function in adults with bronchial asthma. Am. J. Respir. Crit. Care Med. 150 (1994), 629–634.
Ulrik, C.S., Backer, V., Dirksen, A., Pedersen, M., Koch, C., Extrinsic and intrinsic asthma from childhood to adult age: a 10-yr follow-up. Respir. Med. 89 (1995), 547–554.
James, A.L., Palmer, L.J., Kicic, E., Maxwell, P.S., Lagan, S.E., Ryan, G.F., et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am. J. Respir. Crit. Care Med. 171 (2005), 109–114.
Porsbjerg, C., Lange, P., Ulrik, C.S., Lung function impairment increases with age of diagnosis in adult onset asthma. Respir. Med. 109 (2015), 821–827.
Bai, T.R., Vonk, J.M., Postma, D.S., Boezen, H.M., Severe exacerbations predict excess lung function decline in asthma. Eur. Respir. J. 30 (2007), 452–456.
Newby, C., Agbetile, J., Hargadon, B., Monteiro, W., Green, R., Pavord, I., et al. Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J. Allergy Clin. Immunol. 134 (2014), 287–294.
Ulrik, C.S., Backer, V., Dirksen, A., A 10 year follow up of 180 adults with bronchial asthma: factors important for the decline in lung function. Thorax 47 (1992), 14–18.
GINA-Global Initiative for Asthma, Global strategy for asthma management and prevention. Available from: www.ginasthma.org, 2018.
Juniper, E.F., Guyatt, G.H., Epstein, R.S., Ferrie, P.J., Jaeschke, R., Hiller, T.K., Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47:2 (1992), 76–83.
Juniper, E.F., O'Byrne, P.M., Guyatt, G.H., Ferrie, P.J., King, D.R., Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 14 (1999), 902–907.
Nathan, R.A., Kosinski, M., Pendergraft, T.B., Jhingran, P., Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J. Allergy Clin. Immunol. 117 (2006), 549–556.
Dweik, R.A., Boggs, P.B., Erzurum, S.C., Irvin, C.G., Leigh, M.W., Lundberg, J.O., Olin, A.C., Plummer, A.L., Taylor, D.R., American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO)for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO)for clinical applications. Am. J. Respir. Crit. Care Med. 184:5 (2011 Sep 1), 602–615, 10.1164/rccm.9120-11ST PubMed PMID: 21885636; PubMed Central PMCID: PMC4408724.
Guiot, J., Demarche, S., Henket, M., Paulus, V., Graff, S., Schleich, F., et al. Methodology for sputum induction and laboratory processing. J. Vis. Exp., 130, 2017, e56612, 10.3791/56612.
Louis, R., Godinas, L., Schleich, F., Induced Sputum - towards Normal Values, Non Invasive Assessment of Airways Inflammation in Asthma and COPD. 2011 , 113–123.
GINA, https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/, 2018.
Quanjer, P.H., Stanojevic, S., Cole, T.J., Baur, X., Hall, G.L., Culver, B.H., Enright, P.L., Hankinson, J.L., Ip, M.S., Zheng, J., Stocks, J., ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur. Respir. J. 40:6 (2012 Dec), 1324–1343, 10.1183/09031936.00080312 Epub 2012 Jun 27. PubMed PMID: 22743675; PubMed Central PMCID: PMC3786581.
Sposato, B., Predicted values for spirometry may underestimate long-standing asthma severity. Open Respir. Med. J. 10 (2016), 70–78.
Lang, D.M., Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 36 (2015), 418–424.
Schleich, F.N., Manise, M., Sele, J., Henket, M., Seidel, L., Louis, R., Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic in ammation. BMC Pulm. Med., 13(1), 2013, 11.
Schleich, F., Brusselle, G., Louis, R., Vandenplas, O., Michils, A., Pilette, C., et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR). Respir. Med. 108 (2014), 1723–1732.
Almeida, P.C.A., Ponte, E.V., Souza-Machado, A., Cruz, A.A., Longitudinal trends in clinical characteristics and lung function of patients with severe asthma under treatment in Brazil. BMC Pulm. Med., 16, 2016, 141.
Dijkstra, A., Vonk, J.M., Jongepier, H., Koppelman, G.H., Schouten, J.P., ten Hacken, N.H.T., et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 61 (2006), 105–110.
Aziz-Ur-Rehman, A., Dasgupta, A., Kjarsgaard, M., Hargreave, F.E., Nair, P., Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations. Allergy Asthma Clin. Immunol., 13, 2017, 17.
Hancox, R.J., Pavord, I.D., Sears, M.R., Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur. Respir. J., 51, 2018.
Ulrik, C.S., Eosinophils and pulmonary function: an epidemiologic study of adolescents and young adults. Ann. Allergy Asthma Immunol. 80 (1998), 487–493.
Lewis, S.A., Pavord, I.D., Stringer, J.R., Knox, A.J., Weiss, S.T., Britton, J.R., The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults. Chest 119 (2001), 105–114.
Nadif, R., Siroux, V., Boudier, A., le Moual, N., Just, J., Gormand, F., et al. Blood granulocyte patterns as predictors of asthma phenotypes in adults from the EGEA study. Eur. Respir. J. 48 (2016), 1040–1051.
Schleich, F.N., Chevremont, A., Paulus, V., Henket, M., Manise, M., Seidel, L., et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 44 (2014), 97–108.
Frette, C., Annesi, I., Korobaeff, M., Neukirch, F., Dore, M.F., Kauffmann, F., Blood eosinophilia and FEV1. Cross-sectional and longitudinal analyses. Am. Rev. Respir. Dis. 143 (1991), 987–992.
Taylor, R.G., Joyce, H., Gross, E., Holland, F., Pride, N.B., Bronchial reactivity to inhaled histamine and annual rate of decline in FEV1 in male smokers and ex-smokers. Thorax 40 (1985), 9–16.
van Veen, I.H., Ten Brinke, A., Sterk, P.J., Sont, J.K., Gauw, S.A., Rabe, K.F., et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur. Respir. J. 32 (2008), 344–349.
Burrows, B., Knudson, R.J., Camilli, A.E., et al. The “‘horse-racing effect’” and predicting decline in forced expiratory volume in one second from screening spirometry. Am. Rev. Respir. Dis. 135 (1987), 788–793.
Yuan, R., et al. Prediction of the rate of decline in FEV(1)in smokers using quantitative computed tomography. Thorax 64 (2009), 944–949.
Pavord, I.D., Brightling, C.E., Woltmann, G., Wardlaw, A.J., Non-eosinophilic corticosteroid unresponsive asthma. Lancet 353 (1999), 2213–2214.
Demarche, S.F., Schleich, F.N., Henket, M.A., Paulus, V.A., Hees, T.J.V., Louis, R.E., Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre. BMJ Open, 7, 2017 e018186.
Sin, D.D., Man, J., Sharpe, H., Gan, W.Q., Man, S.F.P., Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. J. Am. Med. Assoc. 292 (2004), 367–376.
Kerstjens, H.A., Rijcken, B., Schouten, J.P., Postma, D.S., Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 52 (1997), 820–827.
Janssens, J.P., Pache, J.C., Nicod, L.P., Physiological changes in respiratory function associated with ageing. Eur. Respir. J. 13 (1999), 197–205.
Ortega, H., Yancey, S.W., Keene, O.N., Gunsoy, N.B., Albers, F.C., Howarth, P.H., Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. e1 J Allergy Clin Immunol Pract 6:3 (2018 May Jun), 980–986, 10.1016/j.jaip.2017.12.019 Epub 2018 Feb 15. PubMed PMID: 29398640.
Kanemitsu, Y., Matsumoto, H., Mishima, M., KiHAC Respiratory Medicine Group. Factors contributing to an accelerated decline in pulmonary function in asthma. Allergol. Int. 63 (2014), 181–188.
Coumou, H., Westerhof, G.A., de Nijs, S.B., Zwinderman, A.H., Bel, E.H., Predictors of accelerated decline in lung function in adult-onset asthma. Eur. Respir. J., 51, 2018.
ten Brinke, A., Zwinderman, A.H., Sterk, P.J., Rabe, K.F., Bel, E.H., Factors associated with persistent airflow limitation in severe asthma. Am. J. Respir. Crit. Care Med. 164 (2001), 744–748.
Cibella, F., Cuttitta, G., Bellia, V., Bucchieri, S., D'Anna, S., Guerrera, D., et al. Lung function decline in bronchial asthma. Chest 122 (2002), 1944–1948.
Schleich, F., Malinovschi, A., Seidel, L., Louis, R., Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma. Eur. Respir. J., 48, 2016, OA3035.
Tran, T.N., Khatry, D.B., Ke, X., Ward, C.K., Gossage, D., High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann. Allergy Asthma Immunol. 113 (2014), 19–24.
Price, D.B., Rigazio, A., Campbell, J.D., Bleecker, E.R., Corrigan, C.J., Thomas, M., et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 3 (2015), 849–858.
Hanania, N.A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D.F., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 187 (2013), 804–811.
Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.